A practical reference on BDNF: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
== "Insulin" == "In 1920 the diagnosis of diabetes, particularly in the young and the very young, was essentially a death sentence." "The discovery of insulin represents a real breakthrough that has revolutionized both the therapy and the prognosis of people with diabetes ... Before insulin, diabetes was a dreadful condition associated with bad prognosis and miserable quality of life ... [progressing to] the ineluctable coma-death sequence. In 1889, Joseph von Mering and Oskar Minkowski reported that, in every case, the complete removal of an experimental dog's pancreas produced severe and fatal diabetes. They hypothesized that the consequent diabetic state was "due to loss of an 'internal secretion' of the pancreas rather than [to a loss] of the pancreatic exocrine secretion" (GL.2, p.2). Over the ensuing years, as the endocrine functions of the pancreas (glucagon, insulin, etc.), rather than its exocrine functions (pancreatic juice, etc.), were becoming increasingly better understood, "many investigators [had] endeavoured to obtain some beneficial effect in diabetes mellitus: either by feeding pancreas, or by administration of pancreatic extracts" (FB.2, p.141). The complete chemical structure of insulin was eventually determined by Frederick Sanger and Edward Thompson in 1953 (FS.2; FS.3): and, in 1965 (YW.1; YS.1), the team led by Wang Yinglai (王应睐/王應睞) was not only the first to create synthetic insulin, but was also, in the process, the first to produce a biologically active organic compound from inorganic chemicals.
=== July === 1 July – Balmoral Castle opens to the public for tours for the first time, with daily tours running until 4 August. Steve Carson is to step down as Head of Multi-Platform Commissioning at BBC Scotland in September, in order to take up a senior role at Irish broadcaster RTÉ. 2 July – After rejecting a pay offer in May, waste and recycling staff belonging to Unite in half of Scotland's councils vote to strike. 3 July – Queen Camilla and Prince Edward are formally appointed to the Order of the Thistle at a ceremony in Edinburgh. Moray Council is ordered to pay £346,000 in compensation to a foster family who were wrongly accused of "sexual impropriety" involving children they fostered during the 2010s. 5 July – 2024 United Kingdom general election in Scotland: The SNP suffers heavy losses, going from 48 seats to just nine. With 56 of the 57 seats contested in Scotland declared, Labour win 37, the SNP win nine, while the Conservatives and Liberal Democrats each win five. Starmer ministry: The incoming Labour prime minister Keir Starmer appoints Ian Murray as Secretary of State for Scotland. 6 June – 2024 United Kingdom general election in Scotland: Inverness, Skye and West Ross-shire becomes the final constituency to declare its election results, and sees the number of Liberal Democrat MPs rise to 6 in Scotland after they defeat the SNP to win the seat.
=== Cluster headaches, migraine, and hypnic headache === Studies testing prophylactic use of lithium in cluster headaches (when compared to verapamil), migraine attacks, and hypnic headache indicate good efficacy.
Sources: en.wikipedia.org
== Legislation == The plight of patients with rare diseases became an important political issue in the late 1970s and early 1980s. The US government was subject to pressure from activist groups such as NORD and many others. The chief sponsor of the bill (H.R. 5238) was Henry Waxman (sometimes referred to as the author of the Act), chairman of the Energy and Commerce Subcommittee on Health. It passed the House of Representatives on 14 December 1982, and was similarly approved by voice vote in the Senate on 17 December. On 4 January 1983, President Ronald Reagan signed the ODA into law. Under the ODA drugs, vaccines, and diagnostic agents would qualify for orphan status if they were intended to treat a disease affecting less than 200,000 American citizens. In order to encourage the development of drugs for orphan diseases, the ODA included a number of incentives including seven-year market exclusivity for companies that developed orphan drug, tax credits equal to half of the development costs, later changed to a fifteen-year carry-forward provision and a three-year carry-back that can be applied in profitable year, grants for drug development, fast-track approvals of drugs indicated for rare diseases, and expanded access to the Investigational New Drug Program. The law was also later amended to waive user fees charged under PDUFA. Market exclusivity is particularly appealing to pharmaceutical firms as an incentive to pursue orphan drug development.
=== United Kingdom === The following programs of study have currently been approved by the General Dental Council for the profession of clinical dental technologist. Required prerequisites must be completed prior to enter Clinical Dental Technology Program. On successful completion of the selected courses, individuals are required to register with the General Dental Council to practice legally as a clinical dental technologist.
== Scientific work == Although many of Photaki's important contributions were related to peptide synthesis, her scientific work touched on a large number of topics within organic synthesis. In total she published around 50 papers in international English- or German-language chemical journals.
== Further reading == "Soutien-gorge de sport", in Thierry Adam, Gynécologie du sport (in French). Springer 2012, pp. 305–309. "Facteurs de l'évolution morphologique du sein après arrêt du port du soutien-gorge : étude ouverte préliminaire longitudinale chez 50 volontaires. Olivier Roussel; Jean-Denis Rouillon; Université de Franche-Comté. Faculté de médecine et de pharmacie" (in French). Thèse d'exercice : Médecine : Besançon : 2009.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.